Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravenous (IV) Patient Controlled Analgesia (PCA) With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Hydromorphone Titration: a Multi-center, Phase Ⅲ ，Randomized Trial

NCT04785768 is registered in ClinicalTrials.gov with Fujian Cancer Hospital as lead sponsor.

NCT NCT04785768
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04785768 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intravenous (IV) Patient Controlled Analgesia (PCA) With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Hydromorphone Titration: a Multi-center, Phase Ⅲ ，Randomized Trial
Lead sponsor
Fujian Cancer Hospital
Phase
Phase 3
Overall status
Completed
Start date
July 1, 2021
Completion date
July 1, 2024
Enrollment
1,372 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer pain